Economic evaluation of dasatinib in the treatment of chronic myeloid leukemia patients resistant to imatinib in Chile

Objective. Within the framework of Chronic Myelogenous Leukaemia (CML) treatment in Chile, and based on a previously performed economic evaluation, we compared the costs and cost-effectiveness ratio of using 100 mg/day and 140 mg/day doses of dasatinib with the use of 800 mg/day doses of nilotinib o...

Full description

Bibliographic Details
Main Authors: Milva Caputo, Eleonora Aiello, Juan Esteban Valencia, John Jairo Orozco Giraldo
Format: Article
Language:English
Published: Medwave Estudios Limitada 2011-04-01
Series:Medwave
Subjects:
Online Access:http://dx.doi.org/10.5867/medwave.2011.04.5012